New cancer drug QEQ278 tested in Early-Stage trial
NCT ID NCT05462873
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug, QEQ278, in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Florida Cancer Specialists
Fort Myers, Florida, 33901, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Massachusetts General Hospital Dept. of Mass General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Brussels, 1200, Belgium
-
Novartis Investigative Site
Paris, 75231, France
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Kashiwa, Chiba, 2778577, Japan
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
University of California LA
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Smartphone app aims to combat malnutrition in head and neck cancer patients